{"id":3459,"date":"2021-07-30T15:48:41","date_gmt":"2021-07-30T15:48:41","guid":{"rendered":"http:\/\/inevitablecompany.es\/?p=3459"},"modified":"2021-08-24T19:22:16","modified_gmt":"2021-08-24T19:22:16","slug":"support-communities-involved-in-disease-studies","status":"publish","type":"post","link":"https:\/\/factor-h.org\/es\/support-communities-involved-in-disease-studies","title":{"rendered":"Apoyar a las comunidades que participan en estudios de enfermedades"},"content":{"rendered":"<h5 class=\"wp-block-heading\"><strong>La falta de ayuda continua para las familias pobres involucradas en la investigaci\u00f3n de la enfermedad de Huntington ha sembrado resentimiento y desconfianza, dice Ignacio Mu\u00f1oz-Sanjuan.<\/strong><\/h5>\n\n\n\n<p>Por Ignacio Mu\u00f1oz-Sanjuan<\/p>\n\n\n\n<p>Despu\u00e9s de d\u00e9cadas de investigaci\u00f3n, se est\u00e1 probando en ensayos cl\u00ednicos una terapia gen\u00e9tica para la enfermedad de Huntington. Patrocinado por la empresa farmac\u00e9utica suiza Roche y la estadounidense Ionis Pharmaceuticals, este ensayo se dirige al gen que causa la enfermedad. Si el nuevo tratamiento funciona, podr\u00eda ofrecer una forma de detener la progresi\u00f3n de esta enfermedad gen\u00e9tica, un terrible trastorno neurodegenerativo que ataca principalmente al cerebro. La enfermedad de Huntington es causada por una mutaci\u00f3n de un solo gen que se transmite de manera dominante, por lo que un ni\u00f1o tiene una probabilidad 50% de heredar la afecci\u00f3n si uno de sus padres tiene una sola copia del gen defectuoso. <a href=\"http:\/\/inevitablecompany.es\/wp-content\/uploads\/2021\/07\/Nature_IMS_531141a.pdf\" data-type=\"URL\" data-id=\"http:\/\/inevitablecompany.es\/wp-content\/uploads\/2021\/07\/Nature_IMS_531141a.pdf\">SIGUE LEYENDO.<\/a><\/p>\n\n\n\n<p>FUENTE: Revista Naturaleza<\/p>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Lack of continued help for poor families involved in Huntington\u2019s-disease research has sown resentment and mistrust, says Ignacio Mu\u00f1oz-Sanjuan. By Ignacio Mu\u00f1oz-Sanjuan After decades of research, a genetic therapy for Huntington\u2019s disease is being tested in clinical trials. Sponsored by Swiss pharmaceutical firm Roche and US-based Ionis Pharmaceuticals, this trial targets the gene that causes [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5097,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[98,41],"tags":[],"class_list":["post-3459","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-in-the-press","category-us"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/factor-h.org\/es\/wp-json\/wp\/v2\/posts\/3459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/factor-h.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/factor-h.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/factor-h.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/factor-h.org\/es\/wp-json\/wp\/v2\/comments?post=3459"}],"version-history":[{"count":0,"href":"https:\/\/factor-h.org\/es\/wp-json\/wp\/v2\/posts\/3459\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/factor-h.org\/es\/wp-json\/wp\/v2\/media\/5097"}],"wp:attachment":[{"href":"https:\/\/factor-h.org\/es\/wp-json\/wp\/v2\/media?parent=3459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/factor-h.org\/es\/wp-json\/wp\/v2\/categories?post=3459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/factor-h.org\/es\/wp-json\/wp\/v2\/tags?post=3459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}